Adant 10mg/ml syringe prefilled 2.5ml

Hyaluronic acid has physical properties that make it possible to use this substance as a substitute for synovial fluid disrupted by inflammation. Thus, by restoring the physical characteristics of joint fluid, hyaluronic acid increases mobility and reduces pain in joints affected by osteoarthritis or periarthritis.

In addition, the drug induces the synthesis of high molecular weight hyaluronic acid, similar in structure to “normal” hyaluronic acid, in synovial joints affected by a chronic degenerative or inflammatory process. Without this stimulus, the molecular weight of hyaluronic acid synthesized by synoviocytes is lower than normal.

This mechanism of action combines a prolonged clinical effect of sodium hyaluronate that is 10 times greater than that of intra-articular clearance and metabolism.

The intra-articular administration of this product improves joint function, relieves pain caused by osteoarthritis of the knee and shoulder joints. It improves joint mobility and normalizes the composition of synovial fluid. In addition, this remedy is used for carpal tunnel injection in patients suffering from rhizarthrosis.

Indications

• Osteoarthritis of the knee and Steinbroker syndrome.
• Osteoarthritis of trapezius-carpal joints of I, II and III degrees.
• Pain and limited mobility due to degenerative and traumatic changes in cartilage and synovial fluid of other joints.
  

Active ingredient

Sodium hyaluronate

Composition

1 syringe contains:

The active ingredient:

25 mg sodium hyaluronate;

Excipients:

sodium chloride,

sodium hydrophosphate dodecahydrate,

Concentrated hydrochloric acid,

sodium hydroxide,

water for injection.

.

How to take, the dosage

Nutriarticularly, once a week for 5 consecutive weeks.

The solution should be injected directly into the articular cavity of the knee joint, shoulder joint (articular cavity of the shoulder joint, subacromial sac or sheath of the tendon of the long head of the biceps brachii), cavity of the trapezius carpal joint (first metacarpophalangeal joint) or other affected synovial joint. In the case of injecting solution into the articular cavity of the first metacarpophalangeal joint, two techniques are recommended, depending on the severity of osteoarthritis: lateral external access (severity I rhizarthrosis) and interfinger access through the first commissure (severity II and III rhizarthrosis). The decision to use one or the other technique is made on an individual basis. It is easier to administer the solution under endoscopic control.

In all cases the dose of the solution is adjusted according to the severity of the symptoms.

The results of a multicenter, randomized, double-blind, placebo-controlled trial

(the AMELIA trial) demonstrated the long-term benefits of Adant® Solution after 3 to 4 years of treatment, with improvement in knee osteoarthritis symptoms with one treatment cycle of the Adant® medical device per year.

This product may exacerbate local inflammation in patients with osteoarthritis of the knee if injected into a joint with signs of inflammation. Thus, it is recommended that the solution be injected only after local symptoms of inflammation have resolved.

In rare cases local soreness may occur after injection of the solution. In order to prevent pain after injection, the patient should be instructed to avoid exertion on the area where the solution is injected.

Adant® should be injected directly into the joint cavity, otherwise pain may occur.

Patient special groups

Hepatic impairment. Caution should be exercised when administering Adant® to patients with a history of allergy and to patients with hepatic impairment or impaired liver function.

Elderly age. The solution should be administered with caution because physiological function is usually reduced in elderly patients.

Children. Because the safety of the solution in children has not been established, it should be administered with caution.

Precautionary Precautions for Use

Injection of the Solution

Since Adant® Solution is injected into the joint cavity, the entire process must be done under sterile conditions;

Discontinue treatment if symptoms do not improve within the first 5 weeks of infusion. – If there is a small build-up of synovial fluid, it should be removed by puncture of the joint;

– Avoid injecting Adant® solution into blood vessels and do not apply to the eyes or ocular tissue;

Perspective viscosity of the solution, it is recommended that 21-23 G syringe needles be used.

In case of freezing (see storage conditions) the solution must be brought to room temperature before use.

The solution must be used immediately after opening the package, otherwise its sterility cannot be guaranteed. The solution should only be used once and on one patient and the remainder should be disposed of otherwise cross-infection may occur.

Interaction

The drug should not be mixed with quaternary ammonium salts, including benzalkonium chloride, or with chlorhexidine due to the development of precipitation.

Special Instructions

The drug may cause exacerbation of the inflammatory process in patients with osteoarthritis. In this case it is recommended to administer the drug after the inflammatory symptoms have subsided.

In rare cases pain may occur after injection. To prevent the development of pain after injection of the drug, it is recommended to remain quiet in the affected joint.

The product should be injected directly into the joint cavity otherwise local pain may develop. Caution should be exercised when using Adant in patients with a history of allergic reactions and impaired liver function.

Prescribing for the elderly: The drug should be used with caution as many of the physiological functions of the body have been reduced in the elderly.

Contraindications

• High sensitivity,
• allergy to the ingredients of the drug,
• pregnancy,
• breastfeeding,
• children.

.

Side effects

In some cases, a local allergic reaction such as urticaria and itching may occur. In this case, the drug administration should be stopped and appropriate therapy should be administered.

There have been isolated reports of soreness (mainly transient pain after injection) and swelling.

Patients may complain of swelling, redness, burning sensation and heaviness at the injection site.

The development of shock reactions is extremely rare. If this occurs, further administration of the drug should be discontinued, observation of the patient should be established and appropriate therapy administered.

Similarities

Ostenil, Fermatron, GOU-ON, Ostenil Plus, Fermatron Plus, Haimovis, Hyalripire-10 Chondroreparant, Armaviscon , Optinol, Hyalon prosthesis